Todays Report: Today, Corindus Vascular Robotics’ (CVRS) Buy Rating Reiterate at B. Riley

Today, Corindus Vascular Robotics’ (CVRS) Buy Rating Reiterate at B. Riley

Corindus Vascular Robotics Inc (NYSEMKT:CVRS)‘s stock had its “buy” rating reissued by analysts at B. Riley in a research report issued on Wednesday. They currently have a $3.00 price objective on the stock. B. Riley’s price objective indicates a potential upside of 289.61% from the stock’s previous close.

Separately, Zacks Investment Research cut Corindus Vascular Robotics from a “hold” rating to a “sell” rating in a report on Thursday, August 25th.

Corindus Vascular Robotics (NYSEMKT:CVRS) traded down 1.30% during mid-day trading on Wednesday, reaching $0.76. 65,268 shares of the company were exchanged. The stock’s 50-day moving average price is $0.90 and its 200-day moving average price is $1.19. The stock’s market capitalization is $90.46 million. Corindus Vascular Robotics has a 1-year low of $0.73 and a 1-year high of $3.50.

Corindus Vascular Robotics (NYSEMKT:CVRS) last issued its earnings results on Tuesday, November 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by $0.01. On average, equities research analysts anticipate that Corindus Vascular Robotics will post ($0.26) EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. HealthCor Partners Management LP bought a new position in Corindus Vascular Robotics during the fourth quarter worth about $80,067,000. Wellington Management Group LLP raised its position in Corindus Vascular Robotics by 16.4% in the first quarter. Wellington Management Group LLP now owns 12,052,063 shares of the company’s stock worth $11,937,000 after buying an additional 1,696,393 shares during the last quarter. Clough Capital Partners L P raised its position in Corindus Vascular Robotics by 5.0% in the fourth quarter. Clough Capital Partners L P now owns 2,112,954 shares of the company’s stock worth $6,783,000 after buying an additional 99,700 shares during the last quarter. Vanguard Group Inc. raised its position in Corindus Vascular Robotics by 6.3% in the second quarter. Vanguard Group Inc. now owns 1,934,391 shares of the company’s stock worth $2,766,000 after buying an additional 113,981 shares during the last quarter. Finally, BlackRock Fund Advisors raised its position in Corindus Vascular Robotics by 131.6% in the second quarter. BlackRock Fund Advisors now owns 1,353,007 shares of the company’s stock worth $1,935,000 after buying an additional 768,738 shares during the last quarter.

Related posts

Leave a Comment